Article Tools/Herramientas de artículos
+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeña






White House News White House Drug Control Official Calls For Reauthorization Of His Office

Search Related Content

Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, White House News White House Drug Control Official Calls For Reauthorization Of His Office is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.
Search RobinsPost News & Noticias


White House News White House Drug Control Official Calls For Reauthorization Of His Office | RobinsPost News & Noticias

White House strikes deals for lower prices on obesity drugs


Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some limitations. Read More

White House pauses event after attendee collapses


The White House said the man fainted and is ok. He collapsed as speakers were discussing the deal to reduce the cost of weight loss drugs. Read More

White House shifts focus to tax cuts and drug prices as voters signal economic stress


The White House is keeping up a steady drumbeat of posts on social media about prices and deals for Thanksgiving dinner staples at retailers such as Walmart, Lidl, Aldi and Target. Read More

With White House deal near, Novo and Lilly shares rise


The White House is expected to announce a deal for lower prices of obesity drugs from Novo Nordisk and Eli Lilly on Thursday during an event, according to sources familiar with the situation, pushing ... Read More

White House announces deal to lower weight loss drug prices for many Americans


The Trump administration announced deals on Thursday with pharmaceutical giants Novo Nordisk and Eli Lilly that would lower the cost of GLP-1 drugs for many Americans, including those on Medicare. Read More

White House backs FDA head after ouster of top regulator


The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency. Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus